Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
46.9 USD | -3.63% |
|
-6.94% | -27.91% |
May. 23 | Sector Update: Health Care Stocks Lower Thursday Afternoon | MT |
May. 23 | Inari Medical Sues Imperative Care, Truvic Medical for Alleged Patent Infringement | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 4.59 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.91% | 2.83B | C | ||
+75.69% | 12.57B | B- | ||
+7.77% | 6.66B | C- | ||
+15.10% | 5.5B | D+ | ||
-18.30% | 4.88B | B | ||
+14.96% | 4.1B | - | ||
-20.83% | 3.89B | B- | ||
+44.41% | 2.31B | C- | ||
+1.98% | 2.07B | - | ||
+9.75% | 1.97B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NARI Stock
- Ratings Inari Medical, Inc.